Pamisel Receives Minister of Health and Welfare Award for Innovative Pharmaceutical Company

Pharmicell announced on the 28th that it received the ‘Minister of Health and Welfare Award’ for innovative pharmaceutical companies at the ‘2024 Health Industry Performance Exchange Meeting’.

The Ministry of Health and Welfare annually selects and awards innovative pharmaceutical companies that have contributed to improving public health and the development of the pharmaceutical industry through the development and distribution of excellent medicines. Pharmicell was certified as an innovative pharmaceutical company in 2016 and has maintained its qualification through re-certification.

Pharmicell strengthened its global competitiveness by supplying nucleosides, raw materials for nucleic acid therapeutics, and mPEG, an essential raw material for messenger RNA (mRNA) vaccines, to global pharmaceutical companies such as Thermo Fisher, Merck, and UCB, while maintaining research cooperation relationships. It was recognized for enhancing domestic infectious disease management competitiveness by localizing the production of dNTP (deoxynucleoside triphosphate), a key raw material for molecular diagnostic kits that diagnose viral infections, which had previously been entirely dependent on imports.

A Pharmicell representative emphasized, “We are continuing research on rare and intractable disease treatments through the development of the cell culture solution 'Half-Serum™ DMEM,' which reduces bioethics and environmental issues by half, and advanced regenerative medicine clinical research,” adding, “We received the Minister of Health and Welfare Award in recognition of our significant contributions to the development of the pharmaceutical industry through various innovative research and development.”